Resonance Health logo

RHT - Resonance Health Share Price

A$0.145 0.0  3.6%

Last Trade - 6:10am

Sector
Healthcare
Size
Micro Cap
Market Cap £30.3m
Enterprise Value £28.6m
Revenue £1.97m
Position in Universe 842nd / 1841
Bullish
Bearish
Unlock RHT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RHT Revenue Unlock RHT Revenue

Net Income

RHT Net Income Unlock RHT Revenue

Normalised EPS

RHT Normalised EPS Unlock RHT Revenue

PE Ratio Range

RHT PE Ratio Range Unlock RHT Revenue

Dividend Yield Range

RHT Dividend Yield Range Unlock RHT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RHT EPS Forecasts Unlock RHT Revenue
Profile Summary

Resonance Health Limited is principally engaged in the development and commercialization of technologies and services for the quantitative analysis of radiological images. The Company's segments include Services, Research and Development, and Corporate. The Company's core product is FerriScan, which is a non-invasive liver diagnostic technology used for the measurement of iron in the liver. FerriScan is used for liver iron concentration (LIC) measurement from magnetic resonance imaging (MRI) scans of a patient's liver. The FerriScan analysis procedure produces a mean LIC measurement and a color coded map reflecting the iron distribution across the liver. The Company's product HepaFat-Scan, is a non-invasive method for measuring volumetric liver fat fraction (VLFF) from MRI scans. HepaFat-Scan is provided as an image analysis service. HepaFat-Scan is available for routine clinical use and for use in pharmaceutical company clinical trials.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated May 19, 1987
Public Since October 23, 1987
No. of Shareholders: n/a
No. of Employees: 18
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 402,497,568
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RHT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RHT
Upcoming Events for RHT
Thursday 7th November, 2019 Estimate
Resonance Health Ltd Annual Shareholders Meeting
Similar to RHT
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.